Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free QNTM Stock Alerts

Quantum Biopharma (QNTM) Financials

Quantum Biopharma logo
$2.89 +0.02 (+0.70%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Quantum Biopharma

Annual Income Statements for Quantum Biopharma

This table shows Quantum Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -39 -32 -106 -47 -18 -15 -27
Consolidated Net Income / (Loss)		 -17 -39 -32 -106 -24 -18 -15 -27
Net Income / (Loss) Continuing Operations		 -17 -34 -28 -106 -27 -18 -15 -27
Total Pre-Tax Income 		-17 -34 -28 -106 -28 -18 -15 -27
Total Operating Income		 -19 -22 -31 -34 -27 -24 -16 -15
Total Gross Profit		 0.00 -12 -8.05 -7.44 0.00 0.00 0.00 0.77
Total Revenue		 -4.72 -12 -8.05 -7.44 0.00 0.00 0.00 0.77
Operating Revenue		 -4.72 -12 -8.05 -7.44 - 0.00 0.00 0.77
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 10 23 26 27 24 16 15
Selling, General & Admin Expense		 14 8.41 10 16 14 9.03 9.41 9.05
Research & Development Expense		 - 0.00 7.83 6.33 6.91 3.86 6.08 2.76
Depreciation Expense		 0.13 1.94 3.90 4.05 4.54 2.51 0.49 0.55
Other Operating Expenses / (Income)		 0.00 - - - 1.53 3.84 0.15 2.95
Impairment Charge		 0.00 0.05 0.09 0.00 0.00 4.56 0.00 0.00
Total Other Income / (Expense), net		 1.94 -12 2.24 -72 -0.44 5.56 1.22 -12
Interest Expense		 - - - - 0.05 -0.79 -1.26 0.34
Other Income / (Expense), net		 -5.43 -2.82 3.01 -71 -0.76 4.77 -0.04 -12
Weighted Average Basic Shares Outstanding		 5.91M 7.06M 12.04M 34.95M 595.88K 609.06K 1.14M 3.29M
Weighted Average Diluted Shares Outstanding		 5.91M 7.06M 12.04M 34.95M 595.88K 609.06K 1.14M 3.29M
Weighted Average Basic & Diluted Shares Outstanding		 5.91M 7.06M 12.04M 34.95M 595.88K 609.06K 1.14M 3.89M

Quarterly Income Statements for Quantum Biopharma

No quarterly income statements for Quantum Biopharma are available.

Annual Cash Flow Statements for Quantum Biopharma

This table details how cash moves in and out of Quantum Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 12 -9.93 12 9.94 -49 -34 1.28 -16
Net Cash From Operating Activities		 -18 -14 -19 -21 -47 -34 -9.70 -17
Net Cash From Continuing Operating Activities		 -18 -7.13 -18 -19 -47 -34 -9.70 -17
Net Income / (Loss) Continuing Operations		 -17 -34 -28 -34 -27 -18 -15 -27
Consolidated Net Income / (Loss)		 -17 -34 -28 -34 - -18 -15 -27
Depreciation Expense		 0.13 1.94 3.90 4.05 4.53 2.51 0.49 0.55
Non-Cash Adjustments To Reconcile Net Income		 -1.81 21 6.03 0.00 -25 5.03 3.35 9.06
Changes in Operating Assets and Liabilities, net		 0.32 3.81 1.33 3.50 -0.18 -23 1.38 -0.04
Net Cash From Investing Activities		 -2.96 -0.23 6.51 0.27 0.00 0.00 0.00 0.46
Net Cash From Continuing Investing Activities		 -2.96 0.17 6.48 0.27 0.00 0.00 0.00 0.46
Sale and/or Maturity of Investments		 - 0.46 6.48 - - 0.00 0.00 0.46
Net Cash From Financing Activities		 33 4.01 24 38 -1.93 0.00 11 0.95
Net Cash From Continuing Financing Activities		 33 4.01 24 38 -1.93 0.00 11 0.95
Issuance of Debt		 - - - - 0.00 0.00 0.31 2.11
Issuance of Common Equity		 33 3.43 25 38 0.00 0.00 11 0.34
Other Financing Activities, net		 - 0.62 0.06 - - 0.00 0.00 -1.50
Cash Interest Paid		 - - - - - 0.02 0.01 0.07

Quarterly Cash Flow Statements for Quantum Biopharma

No quarterly cash flow statements for Quantum Biopharma are available.

Annual Balance Sheets for Quantum Biopharma

This table presents Quantum Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 39 43 42 63 38 17 17 11
Total Current Assets		 17 8.56 18 37 18 3.14 6.56 2.20
Cash & Equivalents		 15 5.97 18 35 17 2.76 6.00 1.91
Accounts Receivable		 0.73 1.56 0.16 0.50 0.37 0.23 0.37 0.23
Inventories, net		 0.00 0.71 - - - 0.00 0.12 0.05
Prepaid Expenses		 0.33 0.32 0.57 1.37 0.47 0.16 0.07 0.02
Plant, Property, & Equipment, net		 8.90 8.88 0.00 0.00 -29 0.09 0.08 0.07
Total Noncurrent Assets		 13 26 24 26 21 13 -31 -32
Long-Term Investments		 - - - - 0.00 0.01 1.20 0.46
Noncurrent Note & Lease Receivables		 - - - - 7.45 8.10 3.43 0.00
Intangible Assets		 0.00 17 13 16 12 5.36 4.93 4.51
Other Noncurrent Operating Assets		 13 8.96 1.68 0.83 1.09 0.03 -41 -37
Total Liabilities & Shareholders' Equity		 39 43 42 63 38 17 -2.47 -17
Total Liabilities		 1.28 6.94 5.66 8.83 7.87 4.57 6.68 6.06
Total Current Liabilities		 1.28 3.36 3.70 7.51 7.11 4.20 6.53 5.59
Accounts Payable		 1.28 3.36 3.70 7.51 7.11 4.20 4.36 4.18
Current Deferred Revenue		 - - - - - - 1.00 0.00
Other Current Liabilities		 - - - - - 0.00 1.16 1.40
Total Noncurrent Liabilities		 0.00 3.58 1.96 1.32 0.76 0.37 0.15 0.47
Long-Term Debt		 0.00 1.44 0.38 0.30 0.30 0.30 0.15 0.47
Total Equity & Noncontrolling Interests		 37 36 36 54 33 13 -9.15 -23
Total Preferred & Common Equity		 37 36 36 54 33 13 -8.11 -22
Total Common Equity		 37 36 36 54 33 13 -8.11 -22
Common Stock		 50 74 103 152 174 138 150 170
Retained Earnings		 -19 -59 -91 -126 -144 -158 -172 -198
Other Equity Adjustments		 6.90 22 24 28 2.80 33 14 7.03
Noncontrolling Interest		 - - - - 0.00 -0.33 -1.04 -1.82

Quarterly Balance Sheets for Quantum Biopharma

No quarterly balance sheets for Quantum Biopharma are available.

Annual Metrics And Ratios for Quantum Biopharma

This table displays calculated financial ratios and metrics derived from Quantum Biopharma's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 14,112,490.00 19,161,620.00 40,450,826.00 38,504,282.00 72.00 84.00 84.00
DEI Adjusted Shares Outstanding		 0.00 217,115.00 294,794.00 622,320.00 592,374.00 1.00 84.00 84.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -180.62 -106.88 -170.24 -79.70 -18,230,588.00 -177,565.82 -320,914.76
Growth Metrics		 - - - - - - - -
Profitability Metrics		 - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -13 -16 -21 -24 -19 -17 -11 -11
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -58.08% -127.15% 125.51% 46.76%
Earnings before Interest and Taxes (EBIT)		 -24 -25 -28 -105 -28 -19 -16 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -23 -24 -101 -24 -17 -16 -27
Valuation Ratios		 - - - - - - - -
Leverage & Solvency		 - - - - - - - -
Liquidity Ratios		 - - - - - - - -
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -26 -0.30 -24 5.75 -41 37 -12
Efficiency Ratios		 - - - - - - - -
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 22 32 11 10 -14 9.73 -38 -37
Increase / (Decrease) in Invested Capital		 0.00 9.88 -21 -0.11 -25 24 -48 0.82
Book Value per Share		 $6.33 $5.14 $5.15 $2.83 $0.81 $0.34 ($112,659.26) ($1,796,405.17)
Tangible Book Value per Share		 $6.33 $2.76 $3.24 $1.98 $0.51 $0.20 ($181,185.25) ($2,172,505.75)
Total Capital		 37 38 37 55 33 13 -9.00 -23
Total Debt		 0.00 1.48 0.43 0.42 0.48 0.34 0.15 0.47
Total Long-Term Debt		 0.00 1.48 0.43 0.42 0.48 0.34 0.15 0.47
Net Debt		 -15 -4.49 -17 -35 -17 -2.42 -7.05 -1.89
Capital Expenditures (CapEx)		 2.96 0.29 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.23 -0.77 -2.97 -5.64 -6.24 -3.81 -5.97 -5.29
Debt-free Net Working Capital (DFNWC)		 15 5.20 15 30 11 -1.05 0.03 -3.38
Net Working Capital (NWC)		 15 5.20 15 30 11 -1.05 0.03 -3.38
Net Nonoperating Expense (NNE)		 3.63 23 10 82 4.41 1.58 3.62 16
Net Nonoperating Obligations (NNO)		 -15 -4.49 -26 -44 -47 -3.03 -29 -14
Total Depreciation and Amortization (D&A)		 0.13 1.94 3.90 4.05 4.53 2.51 0.49 0.55
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($29.90) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 294.79K 622.32K 592.37K 1.00 0.00 3.29M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($29.90) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 294.79K 622.32K 595.88K 1.00 0.00 3.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($29.90) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 185.29K 537.62K 595.88K 609.06K 0.00 3.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -16 -21 -24 -19 -13 -11 -11
Debt Service Ratios		 - - - - - - - -
Payout Ratios		 - - - - - - - -

Quarterly Metrics And Ratios for Quantum Biopharma

No quarterly metrics and ratios for Quantum Biopharma are available.


Financials Breakdown Chart

Quantum Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Quantum Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Quantum Biopharma's net income appears to be on a downward trend, with a most recent value of -$26.96 million in 2025, rising from -$16.64 million in 2018. The previous period was -$14.92 million in 2024. See where experts think Quantum Biopharma is headed by visiting Quantum Biopharma's forecast page.

Quantum Biopharma's total operating income in 2025 was -$15.30 million, based on the following breakdown:
  • Total Gross Profit: $769.12 thousand
  • Total Operating Expenses: $15.30 million

Over the last 7 years, Quantum Biopharma's total revenue changed from -$4.72 million in 2018 to $769.12 thousand in 2025, a change of -116.3%.

Quantum Biopharma's total liabilities were at $6.06 million at the end of 2025, a 9.3% decrease from 2024, and a 374.1% increase since 2018.

In the past 7 years, Quantum Biopharma's cash and equivalents has ranged from $1.91 million in 2025 to $35.26 million in 2021, and is currently $1.91 million as of their latest financial filing in 2025.

Over the last 7 years, Quantum Biopharma's book value per share changed from 6.33 in 2018 to -1,796,405.17 in 2025, a change of -28,367,676.8%.


Related Companies

Financial statements for NASDAQ:QNTM last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel